Knight Therapeutics Stock Performance
| GUD Stock | CAD 6.18 0.09 1.44% |
On a scale of 0 to 100, Knight Therapeutics holds a performance score of 12. The company secures a Beta (Market Risk) of 0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Knight Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Knight Therapeutics is expected to be smaller as well. Please check Knight Therapeutics' value at risk, kurtosis, and the relationship between the sortino ratio and semi variance , to make a quick decision on whether Knight Therapeutics' current price movements will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Knight Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, Knight Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Knight Therapeutics Inc. most popular amongst individual investors who own 41 percent of the shares, institutions hold 24 percent - Yahoo Finance | 12/27/2024 |
2 | Technical Patterns and Signals - Stock Traders Daily | 02/14/2025 |
3 | Knight Therapeutics wins target raise at RBC - Cantech Letter | 03/17/2025 |
| Begin Period Cash Flow | 71.7 M | |
| Free Cash Flow | 18.5 M |
Knight |
Knight Therapeutics Relative Risk vs. Return Landscape
If you would invest 525.00 in Knight Therapeutics on December 24, 2024 and sell it today you would earn a total of 93.00 from holding Knight Therapeutics or generate 17.71% return on investment over 90 days. Knight Therapeutics is generating 0.284% of daily returns assuming 1.8436% volatility of returns over the 90 days investment horizon. Simply put, 16% of all stocks have less volatile historical return distribution than Knight Therapeutics, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Knight Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Knight Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Knight Therapeutics, and traders can use it to determine the average amount a Knight Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.154
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GUD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.84 actual daily | 16 84% of assets are more volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Knight Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Knight Therapeutics by adding it to a well-diversified portfolio.
Knight Therapeutics Fundamentals Growth
Knight Stock prices reflect investors' perceptions of the future prospects and financial health of Knight Therapeutics, and Knight Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Knight Stock performance.
| Price To Earning | 133.90 X | ||||
| Revenue | 328.2 M | ||||
| EBITDA | 56.82 M | ||||
| Net Income | (16.84 M) | ||||
| Cash And Equivalents | 302 K | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 69.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 7.53 X | ||||
| Cash Flow From Operations | 28.49 M | ||||
| Earnings Per Share | (0.16) X | ||||
| Market Capitalization | 576.83 M | ||||
| Total Asset | 945.49 M | ||||
| Retained Earnings | 150.89 M | ||||
| Working Capital | 251.09 M | ||||
| Current Asset | 499.48 M | ||||
| Current Liabilities | 6.74 M | ||||
About Knight Therapeutics Performance
By examining Knight Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Knight Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Knight Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 190.38 | 180.86 | |
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Knight Therapeutics performance evaluation
Checking the ongoing alerts about Knight Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Knight Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 328.2 M. Net Loss for the year was (16.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Latest headline from news.google.com: Knight Therapeutics wins target raise at RBC - Cantech Letter |
- Analyzing Knight Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Knight Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Knight Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Knight Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Knight Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Knight Therapeutics' stock. These opinions can provide insight into Knight Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.